Diacetylmorphine for Adults With Opioid Dependence


( Last Updated : July 18, 2022)
Project Line:
Health Technology Review
Project Sub Line:
Rapid Review
Project Number:
RC1437-000

Details


Question

  1. What is the clinical effectiveness of DAM for injection versus methadone or buprenorphine for adults with opioid dependence?
  2. What is the cost-effectiveness of DAM for injection versus methadone or buprenorphine for adults with opioid dependence?
  3. What are the evidence-based guidelines regarding the use of DAM for injection for adults with opioid dependence?


Key Message

Injectable diacetylmorphine might provide more benefits and lower costs compared with oral methadone maintenance therapy in patients with severe opioid use disorder.

The Canadian Research Initiative in Substance Misuse guideline recommends that both injectable diacetylmorphine and hydromorphone should be considered as treatment options for individuals with severe, treatment-refractory opioid use disorder and ongoing illicit injection opioid use, and that the injectable opioid agonist treatment should have an end date to transition to an oral opioid agonist treatment.

No recent studies on the clinical effectiveness of diacetylmorphine for injection in comparison with methadone or buprenorphine were identified.

No cost-effectiveness studies of injectable diacetylmorphine compared with buprenorphine were identified.